CannabisNewsBreaks Archive - CannabisNewsWire

ThursdayNov 30, 2023 12:14 pm

CannabisNewsBreaks – AROYA Unveils CLIMATE ONE, TEROS ONE and AROYA GO at MJBizCon

AROYA by Addium, the preferred cannabis production platform for more than 600 operators across the country, from booth #51005 at MJBizCon in Las Vegas, introduced the latest additions to its portfolio: The CLIMATE ONE Climate Station and The TEROS ONE Substrate Sensors. AROYA’s new environmental and substrate sensors are a means through which to access real-time information and to adjust irrigation and climate conditions. The combination lets growers control environmental factors to influence plant growth patterns and outcomes, leading to more effective and sustainable cultivation practices. “AROYA has set a new standard in precision agriculture for cannabis,” said AROYA CEO…

TuesdayNov 28, 2023 11:52 am

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Tech Lowers Blood Glucose More Effectively than Branded GLP-1 drug Semaglutide Alone, Study Shows

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, is reporting additional positive interim results from its human pilot study evaluating DehydraTECH(TM) technology for the oral delivery of the glucagon-like peptide-1 (“GLP-1”) drug semaglutide, available commercially as Rybelsus(R). According to the report, DehydraTECH-powered semaglutide sustained lower levels of blood glucose from baseline including nearly 10 times lower after 24 hours as well as lower blood-glucose spikes after eating. The company noted that this was the first-ever DehydraTECH test with a “large molecule” drug. According to the report, the study was conducted by a prominent university research center comparing a single…

TuesdayNov 28, 2023 11:23 am

CannabisNewsBreaks – Astrotech Corporation (NASDAQ: ASTC) Unveils AgLAB MVP TM – a Game Changer for Cannabinoid Industry

Astrotech (NASDAQ: ASTC), together with its wholly owned subsidiary, AgLAB Inc., announced the presentation of the AgLAB Maximum Value Process TM (“MVP TM”) at MJBizCon. According to the announcement, the revolutionary process control system has been proven to increase the potency of ending-weight yields and increase revenue by an average of 32%. Utilizing AgLAB’s proprietary mass spectrometer and testing method, MVP TM provides real-time data and feedback, allowing distillers to adjust the parameters (temperature, feed-rate, pressure) and optimize the quality and quantity of each batch of oil. “We are proud to introduce the AgLAB MVP TM, a breakthrough technology that…

MondayNov 27, 2023 2:09 pm

CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Shown to Improve Oral Performance of GLP-1 Drug in Human Pilot Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced positive interim results from a human pilot study currently underway evaluating DehydraTECH(TM) technology for the oral delivery of the glucagon-like peptide-1 (“GLP-1”) drug semaglutide, which is available commercially in the branded product Rybelsus(R). A prominent university research center is performing the study, comparing a single 7 mg semaglutide dose of a Rybelsus tablet (“control”) to a matching dose from Rybelsus that had been compound formulated in capsule form using DehydraTECH processing technology enhancements (“DehydraTECH GLP-1”). According to the update, blood was examined by a third-party laboratory…

WednesdayNov 15, 2023 3:35 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Continues to Advance Patented DehydraTECH(TM)

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, is steadily advancing its patented DehydraTECH(TM) technology for a growing range of applications including oral nicotine, hypertension, antivirals, human hormone therapy, diabetes and more. Through previous clinical trials, DehydraTECH-processed CBD has shown its ability to lower blood pressure in patients over multiple weeks. “That we were able to lower blood pressure in our patient population over multiple weeks using DehydraTECH-CBD is an exceptional discovery, given that previous studies by others using other oral CBD formulations have failed to evidence this sustained benefit,” a recent article quotes Lexaria CEO…

TuesdayNov 14, 2023 2:48 pm

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Q1 Fiscal 2024 Financial Results, Provides Business Update

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today released financial results for the first quarter of the fiscal year 2024, which ended Sept. 30, 2023. “We are pleased with the continued advancements across our pharmaceutical programs and commercial operations. We are particularly excited with the recent candidate selection and official launch of our INM-901 preclinical program targeting the treatment of Alzheimer’s disease, representing a unique and innovative treatment approach compared to current options available to patients. Our commercial subsidiary, BayMedica, continues to make steady progress as a…

ThursdayNov 09, 2023 1:21 pm

CannabisNewsBreaks – The Cannabis Place Announces Opening of Jersey City Dispensary Location

The Cannabis Place has announced the grand opening of its New Jersey flagship dispensary location this Thursday at 4:20 p.m. ET in Jersey City. The Cannabis Place was founded by CEO Osbert Orduña, a first-generation Latino American of Colombian descent. Orduña grew up in New York City public housing, where he was stopped and frisked for the first time when just 13 years old. He was the first person in his family to go to college and earned his service-disabled veteran designation while deployed in Iraq. He is putting his U.S. Marine Corps and life experience and unique perspective to…

FridayNov 03, 2023 2:59 pm

CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM)-Processed CBD Proven Superior in Research

Lexaria (NASDAQ: LEXX), a global innovator in drug delivery platforms, remains on track to submit an Investigational New Drug (“IND”) application for its planned U.S. Phase 1b Hypertension Clinical Trial HYPER H23-1. “Lexaria’s IND submission builds on five previous human clinical studies conducted from 2018 to 2022 and is integral to the successful filing and review of the submission. These studies were carried out in an aggregate total of 134 healthy and hypertensive persons and evidenced significant reductions in resting blood pressure over both acute and multi-week dosing regimens… The company is only aware of a handful of other published…

ThursdayNov 02, 2023 11:28 am

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) to Present Phase 2 Study Results for INM-755 at 12th Annual WCI

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, will be presenting an oral presentation at the 12th World Congress on Itch (“WCI”); the event is scheduled for Nov. 5–7, 2023, in Miami. According to the announcement, the oral presentation is based on an abstract describing the phase 2 clinical study of investigational drug INM-755 cannabinol cream for the treatment of symptoms in patients with rare genetic skin disease called epidermolysis bullosa ("EB"). InMed Pharmaceuticals senior vice president of Clinical and Regulatory Affairs Alexandra Mancini will be presenting. The…

FridayOct 27, 2023 11:49 am

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Secures $5.2M in Private Placement and Preferred Investment Option Offerings

InMed Pharmaceuticals (NASDAQ: INM) is a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs. The company today announced that it has closed its offering for the issuance and sale of 3,012,049 pre-funded warrants and preferred investment options to purchase up to an aggregate of 3,012,049 common shares, at a purchase price of $0.83 per pre-funded and associated preferred investment option, in a private placement priced at-the-market under Nasdaq rules. Per a previously announced definitive agreement with respect to certain of its outstanding preferred investment options issued in November 2022 and exercisable for 3,272,733…

News and publishing service for cannabis related companies

Contact us: 303.498.7722

CannabisNewsBreaks